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Effect of Suppressive DNA on CpG-Induced Immune Activation1
Hiroshi Yamada, Ihsan Gursel, Fumihiko Takeshita, Jackie Conover, Ken J. Ishii,
Mayda Gursel, Saoko Takeshita, and Dennis M. Klinman2
Bacterial DNA and synthetic oligodeoxynucleotides (ODN) containing unmethylated CpG motifs stimulate a strong innate immune
response. This stimulation can be abrogated by either removing the CpG DNA or adding inhibitory/suppressive motifs. Suppres-
sion is dominant over stimulation and is specific for CpG-induced immune responses (having no effect on LPS- or Con A-induced
activation). Individual cells noncompetitively internalize both stimulatory and suppressive ODN. Studies using ODN composed of
both stimulatory and suppressive motifs indicate that sequence recognition proceeds in a 533 direction, and that a 5 motif can
block recognition of immediately 3 sequences. These findings contribute to our understanding of the immunomodulatory activity
of DNA-based products and the rules that govern immune recognition of stimulatory and suppressive motifs. The Journal of
Immunology, 2002, 169: 5590–5594.
B acterial DNA contains bioactive CpG motifs that interactwith Toll-like receptor 9 to trigger an innate immuneresponse (1–6). While CpG-induced immunity helps pro-
tect the host from pathogenic infections (7–10), exposure to stim-
ulatory motifs can have deleterious consequences, ranging from
autoimmune disease to death (11–15).
Krieg et al. (16) were the first to report that neutralizing or
suppressive motifs can selectively block CpG-mediated immune
stimulation. These motifs inhibited cytokine production in vitro
and reduced the adjuvant effects of CpG DNA in vivo. Suppressive
motifs are rich in polyG or -GC sequences, tend to be methylated, and
are present in the DNA of mammals and certain viruses (16–18).
Little is known about the kinetics, magnitude, or nature of the
immune inhibition elicited by suppressive motifs. Current studies
establish that the immunostimulatory activity of CpG DNA can be
reversed within several hours by removal of stimulatory DNA or
addition of suppressive DNA. Stimulatory and suppressive DNA
binds to and interacts with the same cells. When both sequence
types are present on a single strand of DNA, recognition proceeds
in a 533 direction. Suppression is generally dominant over stim-
ulation, although a motif in the 5 position can interfere with rec-
ognition of a motif immediately downstream. Understanding the
rules governing cellular responses to stimulatory and suppressive
motifs should facilitate the design of oligodeoxynucleotides
(ODN)3 for therapeutic uses.
Materials and Methods
Animals
Female BALB/c mice were obtained from The Jackson Laboratory (Bar
Harbor, ME). The mice were housed under specific pathogen-free condi-
tions and were used at 8–20 wk of age. All studies involved protocols
approved by the Center for Biologics Evaluation and Research animal care
and use committee.
Oligodeoxynucleotides
Studies used phosphorothioate-modified ODNs that were synthesized at the
Center for Biologics Evaluation and Research core facility (19). The fol-
lowing ODNs were used: immunostimulatory, ODN1466(TCAACGTTGA)
and ODN1555 (GCTAGACGTTAGCGT); control, ODN1471 (TCAAGCT
TGA) and ODN1612(GCTAGAGCTTAGGCT); and suppressive, ODN1502
(GAGCAAGCTGGACCTTCCAT) and ODNH154 (CCTCAAGCTTGAG
GGG). The underlined bases represent the 10-mer sequences that were
incorporated into complex multideterminant ODN used in some experi-
ments. There was no detectable protein or endotoxin contamination of
these ODN.
Mammalian DNA was purified from BALB/c spleens (Wizard Genomic
DNA purification kit; Promega, Madison, WI).Escherichia coli DNA was
obtained from Life Technologies (Gaithersburg, MD). Endotoxin contam-
ination in these preparations was0.1 U/ml after purification (20). Dou-
ble-stranded DNA was converted to ssDNA by heat denaturing at 95°C for
5 min, followed by immediate cooling on ice.
Cytokine ELISAs
Spleen single-cell suspensions were washed three times and resuspended in
RPMI 1640 supplemented with 5% heat-inactivated FCS, 1.5 mML-glu-
tamine, and 100 U/ml of penicillin/streptomycin. Cells (5 105/well) were
cultured in flat-bottom microtiter plates (Costar, Corning, NY) with 1M
ODN for 18–24 h. Culture supernatants were collected, and cytokine levels
were measured by ELISA. In brief, 96-well Immulon H2B plates (Thermo
LabSystems, Franklin, MA) were coated with cytokine-specific Abs and
blocked with PBS 1% BSA as previously described (21). Culture super-
natants were added, and bound cytokine was detected by the addition of
biotin-labeled secondary Abs, followed by phosphatase-conjugated avidin
and a phosphatase-specific colorimetric substrate (PNPP; Pierce, Rockford,
IL). Standard curves were generated using recombinant cytokines. The
detection limit for these assays was 0.8 U/ml for IFN-, 0.1 ng/ml for IL-6,
and 0.1 ng/ml for IL-12. All assays were performed in triplicate.
Cytokine-specific ELISPOT assays
A spleen single-cell suspension prepared in RPMI 1640 plus 5% FCS was
serially diluted onto plates precoated with anti-cytokine Abs (21). Cells
were incubated with 1M ODN at 37°C for 8–12 h, and the secretion of
cytokine was detected colorimetrically as previously described (21).
Cell surface binding and internalization of ODN
Spleen cells (2 106/ml) were incubated with 1M of unlabeled and/or
fluorescent-labeled ODN for 10 min at 4°C (binding experiments) or for
1 h at 37°C (uptake experiments). Cells were washed, fixed, and analyzed
by FACScan (BD Biosciences, San Jose, CA) (22).
Section of Retroviral Immunology, Center for Biologics Evaluation and Research,
Food and Drug Administration, Bethesda, MD 20892
Received for publication April 19, 2002. Accepted for publication September 6, 2002.
The costs of publication of this article were defrayed in part by the payment of page
charges. This article must therefore be hereby markedadvertisement in accordance
with 18 U.S.C. Section 1734 solely to indicate this fact.
1 This work was supported in part by a grant from the National Vaccine Program. The
assertions herein are the private ones of the authors and are not to be construed as
official or as reflecting the views of the Food and Drug Administration at large.
2 Address correspondence and reprint requests to Dr. Dennis M. Klinman, Building
29A, Room 3D10, Center for Biologics Evaluation and Research, Food and Drug
Administration, Bethesda, MD 20892. E-mail address: klinman@cber.fda.gov
3 Abbreviations used in this paper: ODN, oligodeoxynucleotide.
The Journal of Immunology
Copyright © 2002 by The American Association of Immunologists, Inc. 0022-1767/02/$02.00












Statistically significant differences between two groups were determined
using the Wilcoxon rank-sum test. When comparing more than two groups,
differences were determined using a two-tailed nonparametric ANOVA
with Dunn’s post-test analysis. A value of p  0.05 was considered
significant.
Results
Mammalian DNA suppresses CpG DNA-induced immune
activation
Single-stranded bacterial DNA and synthetic ODN containing un-
methylated CpG motifs stimulate immune cells to mature, prolif-
erate, and produce cytokines, chemokines, and Ig (2–5). These
effects can be blocked by polyG- and/or GC-rich DNA motifs (16,
23). Scores of ODNs were synthesized and tested to identify motifs
that selectively inhibited CpG-induced immune responses. The
two most active of these suppressive ODN (ODN1502 (GAG
CAAGCTGGACCTTCCAT) and ODNH154 (CCTCAAGCTT
GAGGGG)) were selected for detailed study. As shown in Fig. 1,
these suppressive ODN blocked a majority of the IFN- produc-
tion induced by bacterial DNA or CpG ODN ( p  0.01). Sup-
pressive ODN were neither toxic nor broadly immunosuppressive,
as they did not interfere with the mitogenic activity of LPS or Con
A (Fig. 1 and data not shown).
The activity of suppressive ODNs was concentration dependent,
with 50% suppression being achieved at a suppressive ODN:CpG
ODN ratio of 1:3 (Fig. 2). To examine the kinetics of this inhi-
bition, suppressive ODN were added to BALB/c spleen cells at
various times after CpG-induced stimulation. Maximal inhibition
was observed when suppressive ODN were coadministered with
CpG ODN, although statistically significant inhibition persisted
when suppressive ODN were added up to 3 h later (Fig. 3). These
findings suggest that CpG-induced immune activation is an ongo-
ing process and can be inhibited after the stimulatory signal is
delivered.
FIGURE 1. Effect of suppressive ODN on CpG DNA and mitogen-
induced IFN- production. BALB/c spleen cells were stimulated with 1
M CpG ODN (ODN1555, ODN1466), 50 g/ml of bacterial DNA, 5 g/ml
of Con A, or 5 g/ml of LPS. The response of these cultures (f) was
compared with that of cells costimulated with 1 M control ODN1612 ( ),
suppressive ODN1502 (o), or suppressive ODNH154 (p). The number of
IFN--secreting cells was determined by ELISPOT after 18 h. Data rep-
resent the average  SD of triplicate cultures. The experiment was re-
peated three times with similar results.
FIGURE 2. Concentration effects of suppressive ODN. BALB/c spleen
cells were stimulated with 1 M CpG ODN1555 or ODN1466 plus increas-
ing amounts of suppressive ODN1502 or ODNH154. Cytokine levels in cul-
ture supernatants were measured by ELISA after 24 h. Results represent the
mean  SD of four different experiments.
FIGURE 3. Kinetics of suppressive ODN. BALB/c spleen cells were
stimulated with 1 M CpG ODN1555. At various times, 1 M suppressive
ODN1502 was added. Cytokine levels in supernatants were measured by
ELISA after 24 h. Results represent the mean of two independent experiments.
FIGURE 4. Effect of removing CpG ODN from cultured cells. CpG
ODN1555 (1 M) was added to BALB/c spleen cells at time zero. The cells
were washed free of this ODN after various incubation periods. IFN- and
IL-12 levels in culture supernatants were measured by ELISA after 24 h.
Results represent the average  SD of duplicate cultures. Similar results
were obtained in studies of CpG ODN1466.
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To test this conclusion, spleen cells were incubated with CpG
ODN for various periods, and cytokine production was analyzed
after 24 h. Cells stimulated with CpG DNA for 8 h produced 90%
as much cytokine as cells stimulated continuously for 24 h (Fig. 4).
Cells treated with CpG ODN for only 4 h produced half as much
cytokine, while cells treated with CpG DNA for 2 h showed only
minimal activation (Fig. 4). These findings support the conclusion
that CpG-induced cellular activation is reversible for several hours.
Suppressive ODN do not block CpG ODN uptake or induce the
production of inhibitory factors
The results described above indicate that CpG-induced immune
activation can be reversed either by adding suppressive ODN or by
removing stimulatory ODN. This suggests that suppressive ODN
might block the ongoing uptake of CpG DNA. Yet FACS analysis
demonstrated that neither cell surface binding nor internalization
of FITC-labeled CpG ODN was significantly reduced by suppres-
sive ODN at concentrations that blocked cytokine production by
75% (Fig. 5 and data not shown). Moreover, precisely the same
cells that bound and internalized CpG ODN interacted with sup-
pressive ODN (Fig. 6).
The possibility that suppressive motifs might induce the pro-
duction of a factor that blocked CpG-dependent immune stimula-
tion was then investigated. Initial studies established that BALB/c
spleen cells preincubated with suppressive ODN remained unre-
sponsive to CpG-induced stimulation for several hours (Table I,
line 3). If this nonresponsive state was mediated by a soluble factor
(or inhibitory cell-cell interactions) then cells pretreated with sup-
pressive ODN should block CpG-induced stimulation of naive
splenocytes. As shown in Table I, cells treated with suppressive
ODN had no significant effect on CpG-dependent cytokine pro-
duction by fresh spleen cells.
Cellular recognition of suppressive vs stimulatory motifs
The above studies establish that suppressive motifs on one strand
of DNA block the immune activation induced by stimulatory mo-
tifs on a different strand (i.e., trans-suppression). To better under-
stand the interaction between suppressive and stimulatory motifs,
ODNs containing both were synthesized. A set of four 20-mer
ODNs was constructed in which one of two different CpG motifs
was placed immediately 5 to either of two suppressive motifs
(referred to as [CpG-Sup] ODN).
All four of these [CpG-Sup] ODN were stimulatory, triggering
murine spleen cells to produce IL-6, IL-12, and IFN- to the same
extent as an ODN of the same length in which the suppressive
motif was replaced by a control sequence (i.e., one that was neither
stimulatory nor suppressive; Table II). [CpG-Sup] ODNs did not
inhibit the immune activation induced by an independent CpG
ODN (Table II). These results suggest that a suppressive motif is
inactive when located immediately 3 to a CpG motif on the same
strand of DNA.
To better understand this phenomenon, longer ODNs were syn-
thesized in which the CpG and suppressive motifs were separated
by progressively longer CT spacers. Adding a 5-base spacer gen-
erated an ODN that was still stimulatory (Table III). However,
separating the motifs by 10 bases yielded ODNs that were sup-
pressive, demonstrated by their ability to block the stimulatory
activity of coadministered CpG ODNs (Table III). The trivial pos-
sibility that the CT spacer somehow reduced CpG activity was
eliminated by substituting a control motif for the 3 suppressive
motif. The resulting ODNs were fully stimulatory (Table III and
data not shown).
FIGURE 5. Suppressive ODN do not block the binding or uptake of
CpG ODN. BALB/c spleen cells were incubated with 1 M CpG ODN1555
(f) plus 1 M suppressive ODN1502 (u) or control ODN1612 () for 2 h.
The percentage of cells that bound or internalized the CpG ODN was
determined by FACS. Similar results were obtained using CpG ODN1466,
suppressive ODNH154, and control ODN1471.
FIGURE 6. Binding and internaliza-
tion of suppressive and CpG ODN.
BALB/c spleen cells were incubated with
1 M CpG ODN1555 and/or 1 M sup-
pressive ODN1502 at 4
oC for 10 min or at
37oC for 2 h. Note that the same cells
bound and internalized both CpG and
suppressive ODN. Binding increased as
the time of incubation was prolonged
(Fig. 5).
Table I. Effect of mixing cells treated with suppressive vs
stimulatory ODNa





Pretreatment Fresh Cells IL-6 IL-12
  CpG 100  13 100  6
  Control 3  2 7  2
  CpG 9  6 6  2
  Control 0  0 0  0
  CpG 86  16 105  12
  Control 0  0 0  0
a BALB/c spleen cells were treated with 1 M suppressive ODNH154 for 2 h and
then washed (first column). These cells were added to naive splenocytes (second
column) plus 1 M control (ODN1471) or CpG (ODN1555) ODN. IL-6 and IL-12
levels in culture supernatants were measured by ELISA after 18 h. The percentage of
maximal cytokine production was calculated by the formula: (cytokine produced by
treatment group)  (background)/(cytokine produced by fresh cells stimulated with
CpG ODN)  (background)  100%, where the background was cytokine levels in
fresh cells cultured in medium alone. Results represent the average  SD of triplicate
assays, each standardized to the response induced by bacterial DNA (62 pg/ml IL-6;
134 pg/ml IL-12).
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The impact of placing a suppressive motif 5 to a CpG motif was
then examined. ODNs with a suppressive motif in the 5 position
induced little or no immune activation even when the CpG motif
was shifted up to 20 bp downstream from the suppressive motif
(Tables II and III). This lack of activity could not be attributed to
the 3 location of the CpG motif, since CpG ODNs with a control
sequence at the 5 end were stimulatory. All ODNs containing a
suppressive motif in the 5 position also inhibited the stimulatory
activity of a coadministered CpG ODN (Tables II and III). These
findings suggest that the relative positions of stimulatory and sup-
pressive motifs determine the immunomodulatory properties of DNA.
Discussion
DNA has multiple and complex effects on the immune system. The
innate immune response triggered by unmethylated CpG motifs
present in bacterial DNA improve host resistance to infectious
pathogens (7, 9, 10, 24). Yet CpG stimulation can increase the
host’s susceptibility to autoimmune disease and death (11–14, 25,
26). This work examines the ability of suppressive motifs to spe-
cifically down-regulate CpG-induced immunity.
Previous studies established that CpG DNA interacts with TLR9
to trigger the translocation of NF-B from the cytoplasm to the
nucleus and the subsequent up-regulation of cytokine gene expres-
sion (1, 6, 27–30). Current results demonstrate that this is not an
all-or-none phenomenon. Although NF-B translocation is initi-
ated within minutes of CpG administration (29), the subsequent
increase in cytokine production occurs over a period of hours (2)
and is significantly reduced by the addition of suppressive ODN or
the removal of stimulatory CpG DNA (Figs. 3 and 4). Consistent
with these findings, suppressive motifs were recently shown to
down-regulate CpG-dependent NF-B and AP-1 induction (17,
18). These observations suggest that CpG motifs must continu-
ously signal receptive cells for triggering to persist.
The sequence and length of a DNA strand determine its activity.
By synthesizing and testing scores of ODNs, our laboratory and
that of Krieg et al. independently identified G- and GC-rich motifs
that selectively block CpG-dependent activation (16). Of note,
Zhao et al. (31) showed that not all GC-rich repeats confer sup-
pressive activity, while Halpern et al. (32) showed that ODNs con-
taining runs of 15 polyGs can inhibit both CpG- and mitogen-
induced immune responses. Suppressive activity appears to depend
upon an ODNs secondary/tertiary structure, although sequence-
nonspecific competition for ODN uptake is also possible (28). In
this context, G-rich regions facilitate the formation of complex
intra- and interchain Hoogsteen hydrogen bonds (33, 34). Depend-
ing on how these chains fold, activity may be gained or lost.
To validate the findings in this report, all experiments were re-
peated with multiple ODNs containing different combinations of
suppressive and/or CpG motifs. In addition, the critical role of the
suppressive motifs was established by showing that control motifs
neither enhanced nor prevented CpG induced immune stimulation.
Table II. Effect of motif position on immunostimulatory activitya
Location of Motifs (533)
No. of Cytokine-Secreting Cells
IL-6 IL-12 IFN-
CpG ODNb 79  3 1980  230 260  40
[CpG-Sup] ODNb 72  14 2080  480 230  60
[Sup-CpG] ODN 0  0 140  30 0  0
[CpG-Cont] ODNb 64  12 2210  130 284  34
[Cont-CpG] ODNb 80  11 1942  88 238  28
[Cont-Sup] ODN 8  2 184  34 36  8
[CpG-Sup] ODN  Sup ODN 4  2 226  38 28  6
[Sup-CpG] ODN  CpG ODN 7  3 250  32 34  9
a BALB/c spleen cells (106) were coincubated with 1 M of each ODN. Complex
ODN (20 bp in length) were constructed from 10-mer encoding suppressive (Sup;
GAGCAAGCTG and AGCTTGAGGG), stimulatory (CpG; TCACGTTGA and TA
GACGTTAG), or control (Cont; TCAAGCTTGA and TAGAGCTTAG) motifs. The
number of cytokine-secreting cells per 106 cells was determined by ELISPOT after
24 h of stimulation. Results represent the average  SD of triplicate assays involving
at least two ODN of each type.
b Stimulatory ODN, p  0.05.
Table III. Effect of distance between motifs on ODN activitya
ODN
Cytokine-Producing Cells (% maximum)
IL-6 IL-12 IFN-
CpG ODNb 100  11 100  7 100  10
CpG ODNb  Cont ODN 97  14 98  9 100  17
CpG ODNb  Sup ODN 16  6 21  6 18  5
LPS 100  2 99  2 100  2
LPS  Sup ODN 94  7 94  5 92  7
[CpG-Sup] ODNb 87  12 100  14 92  14
[CpG-5 bases-Sup] ODNb 100  4 100  21 100  22
[CpG-10 bases-Sup] ODN 38  6 64  15 42  7
[CpG-20 bases-Sup] ODN 7  4 48  13 24  8
[CpG-Cont] ODNb 94  7 100  14 99  11
[Sup-CpG] ODN 0  0 0  0 0  0
[Sup-20 bases-CpG] ODN 8  5 9  3 2  1
[CpG-Sup] ODNb  CpG ODNb 100  16 100  15 98  13
[CpG-5 bases-Sup] ODNb  CpG ODNb 100  18 100  11 98  20
[CpG-10 bases-Sup] ODN  CpG ODNb 58  7 75  9 66  9
[CpG-20 bases-Sup] ODN  CpG ODNb 27  5 26  10 30  8
[Sup-CpG] ODN  CpG ODNb 9  4 11  4 8  5
[Sup-20 bases-CpG] ODN  CpG ODNb 5  1 9  3 13  2
a BALB/c spleen cells were stimulated in vitro with 1 M of each ODN (or 5 g/ml LPS), and the number of cells activated
to secrete cytokine was determined 8 h later by ELISPOT. The percentage of cells activated to secrete cytokine was calculated
by the formula: (number of cells activated by test ODN)  (background)/(number of cells activated by CpG ODN)  (back-
ground)  100%. Multiple combinations of the CpG, suppressive and control 10-mer motifs described in Table II were used in
these studies and gave similar results in these experiments. Results represent the average of two to four assays per data point.
Table II shows typical numbers of cytokine-secreting cells per 106 cells.
b Stimulatory ODN, p  0.05.
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The data in Tables II and III and Fig. 6 suggest that suppressive
and stimulatory motifs are active on the same cells, and that their
relative locations on a DNA strand determine the magnitude and
nature of the resultant response. The results indicate that 1) cellular
recognition of stimulatory and suppressive motifs proceeds in a
533 direction; and 2) suppression is generally dominant over
stimulation, however, 3) when a CpG motif is immediately 5 to a
suppressive motif, stimulation dominates. A likely explanation for
the latter phenomenon is that molecules involved in recognizing
the 5 motif block the cell’s ability to interact with an immediately
adjacent suppressive motif, perhaps due to steric hindrance. When the
distance between motifs exceeds 10 bases, this effect dissipates.
Our finding that the relative location of CpG vs suppressive
motifs on a single strand of DNA influences the resultant immune
response strongly suggests that individual cells recognize both mo-
tifs. Experiments using labeled ODNs demonstrate that both types
of DNA enter the same cells (Fig. 5 and data not shown). Indeed,
the possibility that one type of cell responds only to stimulatory
motifs and another only to suppressive motifs is inconsistent with
the results in Tables II and III. Moreover, the data shown in Table
I indicate that cells exposed to suppressive ODNs do not produce
factors or interact on a cell-to-cell basis in such a way as to inhibit
other cells from responding to CpG motifs.
Suppressive ODNs could be of use in several therapeutic set-
tings. CpG motifs in antisense and gene therapy vectors contribute
to the immune recognition of transfected cells (35). Introducing
suppressive sequences 5 to CpG motifs in these vectors might
dampen this immune response and prolong the vector’s in vivo
activity (16). Alternatively, the immunogenicity of DNA vaccines
might be improved by deleting suppressive motifs (16). Finally,
suppressive ODN may prove useful in situations where the host’s
response to bacterial DNA contributes to pathology, as in septic
shock or autoimmune disease (11, 25, 36, 37). Since suppressive
ODN precisely target the inflammatory response induced by CpG
DNA, these therapies may avoid the deleterious side effects asso-
ciated with generalized immunosuppressive regimens.
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